{"entity":{"id":"tac-003","kind":"drug","name":"TAC-003","aka":["Nectin-4 TRAAC"],"tldr":"TAC-003 is an experimental toll-like receptor agonist antibody conjugate from Tallac Therapeutics, in preclinical development for cancer; its current status is not stated.","summary":"TAC-003 (Nectin-4 TRAAC) is a toll-like receptor agonist antibody conjugate (TRAAC) from Tallac Therapeutics. A TRAAC directed at Nectin-4; the source names only the target. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Preclinical data featured at SITC 2023; no later update found on the company site. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Tallac Therapeutics: tallactherapeutics.com","url":"https://www.tallactherapeutics.com/news/tallac-presents-first-clinical-data-for-tac-001-at-sitc-2023/"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["nectin4"],"drugs":[],"companies":["tallac-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"TAC-003","modality":"Toll-like receptor agonist antibody conjugate (TRAAC)","mechanism":"A TRAAC directed at Nectin-4; the source names only the target.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tac-003/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}],"company":[{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/"}]}}